Table 4.
Comparison of pre-therapy and post-therapy laboratory data in 50 SLE patients receiving pulse therapy of methylprednisolone without taking NSAIDs/aspirin
| Pre-therapy | Post therapy | P-value | |
|---|---|---|---|
| Gastric injury scale median (range) | 0.70 ± 1.15 | 0.64 ± 1.16 | 0.180 |
| 0 (0–4) | 0 (0–4) | ||
| Gastric pH | 3.2 ± 1.4 | 3.0 ± 1.5 | 0.460 |
| Serum gastrin (pg ml−1) | 90.6 ± 53.9 | 91.4 ± 63.6 | 0.893 |
| Serum pepsinogen I (ng ml−1) | 120.5 ± 53.2 | 119.5 ± 52.7 | 0.864 |
| Serum TXB2 (pg ml−1) (COX-1 activity) | 38 668 ± 44 514 | 40 060 ± 44 619 | 0.532 |
| Serum PGE2 (pg ml−1) (COX-2 activity) | 468.5 ± 193.0 | 388.2 ± 143.1 | 0.001 |
| Gastric TXB2 (ng mg−1 protein) | 1 665.5 ± 1 239.6 | 1 821.1 ± 1 343.4 | 0.732 |
| Gastric PGE2 (ng mg−1 protein) | 719.6 ± 562.8 | 828.3 ± 582.7 | 0.171 |
SLE, systemic lupus erythematous; NSAIDs, nonsteroidal anti-inflammatory drugs; TXB2, thromboxane B2; COX, cyclooxygenase; PGE2, prostaglandin E2. Data are expressed as means ± SD.